Fundies. English
Segment disclosures
Company overviewCodexis, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
98 dimension combinations 752 retained observations 21 reported periods Partial retained history
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Product Sales · Biotherapeutic Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 0 | USD | 20190508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
Operating Segments · Product Sales · Biotherapeutics Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20220228 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220228 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20220228 | Open filing evidence |
Operating Segments · Product Sales · Core Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 30690000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 10226000 | USD | 20220509 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5100000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10351000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 24588000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 6249000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 14236000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 7988000 | USD | 20200508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 8405000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 18291000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Operating Segments · Product Sales · Novel Biotherapeutics
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-01-01 – 2018-12-31 | 0 | USD | 20190301 | Open filing evidence |
Operating Segments · Product Sales · Performance Enzymes
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-01-01 – 2018-12-31 | 25590000 | USD | 20190301 | Open filing evidence |
Operating Segments · Researchand Development Revenue · Biotherapeutic Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20190508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4821000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 10507000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Operating Segments · Researchand Development Revenue · Biotherapeutics Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 14239000 | USD | 20220228 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20220228 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20220228 | Open filing evidence |
Operating Segments · Researchand Development Revenue · Core Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 2409000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4003000 | USD | 20220509 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10073000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 16512000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4340000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 6440000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 2099000 | USD | 20190508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 3720000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 15728000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Operating Segments · Researchand Development Revenue · Novel Biotherapeutics
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 567000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6079000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3324000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7441000 | USD | 20231103 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20190301 | Open filing evidence |
Operating Segments · Researchand Development Revenue · Performance Enzymes
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 3315000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 12696000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3104000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7398000 | USD | 20231103 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 21483000 | USD | 20190301 | Open filing evidence |
Operating Segments · Product · Novel Biotherapeutics
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20231103 | Open filing evidence |
Operating Segments · Product · Performance Enzymes
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 5395000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 24807000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 28042000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 93376000 | USD | 20231103 | Open filing evidence |
Operating Segments · Biotherapeutic Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20220509 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3868000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7670000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3803000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7461000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 11258000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20200508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4821000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 10507000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Operating Segments · Biotherapeutic Segment · Researchand Development Revenue
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3803000 | USD | 20220509 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20210507 | Open filing evidence |
Operating Segments · Biotherapeutics Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 11978000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 14239000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20220228 | Open filing evidence |
Operating Segments · Core Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 33099000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 32584000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 68397000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 14229000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 13005000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 31385000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 10874000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 20424000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 41100000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 10589000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 20676000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 10087000 | USD | 20200508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 12125000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 34019000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Operating Segments · Core Segment · Product Sales
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 28731000 | USD | 20211105 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 8401000 | USD | 20211105 | Open filing evidence |
Operating Segments · Novel Biotherapeutics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 567000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6079000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3324000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7441000 | USD | 20231103 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20190301 | Open filing evidence |
Operating Segments · Performance Enzymes
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 8710000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 37503000 | USD | 20231103 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 19308000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 28794000 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 31146000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 100774000 | USD | 20231103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 36530000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 69629000 | USD | 20230803 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 47073000 | USD | 20190301 | Open filing evidence |
Product Sales · Operating Segments · Biotherapeutic Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 0 | USD | 20210507 | Open filing evidence |
Product Sales · Operating Segments · Biotherapeutics Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20230227 | Open filing evidence |
Product Sales · Biotherapeutic Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 0 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 0 | USD | 20190508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
Product Sales · Biotherapeutics Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20220228 | Open filing evidence |
Product Sales · Core Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 30690000 | USD | 20220509 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 14717000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 24943000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 10226000 | USD | 20220509 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 30220000 | USD | 20210301 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4504000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 9604000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5100000 | USD | 20200508 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 29465000 | USD | 20210301 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10351000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 24588000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 6249000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 14236000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 7988000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 25590000 | USD | 20210301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 8405000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 18291000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Product Sales · Core Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 29465000 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 25590000 | USD | 20210301 | Open filing evidence |
Product Sales · Performance Enzymes · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=cdxs:ProductSalesMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 29465000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 25590000 | USD | 20200228 | Open filing evidence |
Researchand Development Revenue · Operating Segments · Biotherapeutic Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20201106 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 20201106 | Open filing evidence |
Researchand Development Revenue · Operating Segments · Biotherapeutics Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 14239000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20230227 | Open filing evidence |
Researchand Development Revenue · Operating Segments · Core Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 3853000 | USD | 20211105 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 4604000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5774000 | USD | 20200508 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 2099000 | USD | 20200508 | Open filing evidence |
Researchand Development Revenue · Operating Segments · Performance Enzymes
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 8260000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 9382000 | USD | 20230803 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1885000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4294000 | USD | 20230803 | Open filing evidence |
Researchand Development Revenue · Biotherapeutic Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 1876000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4117000 | USD | 20220805 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3868000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7670000 | USD | 20220805 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7461000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 11258000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20200508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4821000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 10507000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Researchand Development Revenue · Biotherapeutic Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2020-06-30 | 7461000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 11258000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20200508 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20200508 | Open filing evidence |
Researchand Development Revenue · Biotherapeutics Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 11978000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 14239000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20220228 | Open filing evidence |
Researchand Development Revenue · Core Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 1885000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4294000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2409000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3853000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 14723000 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 6868000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 10872000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4003000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 4604000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 13380000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 3002000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 8775000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5774000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10073000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 16512000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4340000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 6440000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 2099000 | USD | 20200508 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 3720000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 15728000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Researchand Development Revenue · Core Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-07-01 – 2020-09-30 | 4604000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 13380000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 3002000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 8775000 | USD | 20200810 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10073000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 16512000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4340000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 6440000 | USD | 20200810 | Open filing evidence |
Researchand Development Revenue · Novel Biotherapeutics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 3496000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20230504 | Open filing evidence |
Researchand Development Revenue · Novel Biotherapeutics · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 2015000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 5511000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 3496000 | USD | 20230504 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1876000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4117000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20230504 | Open filing evidence |
Product · Operating Segments · Performance Enzymes
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 11048000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 19412000 | USD | 20230803 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 34645000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 65335000 | USD | 20230803 | Open filing evidence |
Product · Novel Biotherapeutics · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20230803 | Open filing evidence |
APAC · Biotherapeutic Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=cdxs:APACMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210507 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 0 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 0 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 0 | USD | 20190508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
APAC · Core Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=cdxs:APACMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 1808000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 18154000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 23661000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 81243000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 27481000 | USD | 20220509 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 13440000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 20262000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 6821000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 7655000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 15876000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4747000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 8221000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3474000 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 6995000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 15516000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 3502000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 8522000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5019000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 22863000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 6357000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 15483000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Americas · Biotherapeutic Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 1168000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 3653000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1179000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 1817000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 6015000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 2141000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 4199000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 2058000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 2632000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 10591000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 5733000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 7960000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 2226000 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 0 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 0 | USD | 20190508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 38000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 0 | USD | 20181109 | Open filing evidence |
Americas · Biotherapeutics Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 4911000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 7367000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 13241000 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20220228 | Open filing evidence |
Americas · Core Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 4278000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 8865000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 12089000 | USD | 20230227 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3654000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 8514000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2553000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 16114000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5999000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 12573000 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3703000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 6574000 | USD | 20210806 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 2871000 | USD | 20220509 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 11111000 | USD | 20230227 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 3209000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 7381000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1173000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 4171000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 2999000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 2706000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 9620000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4076000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 6913000 | USD | 2019-08-07 · 00:35:18.000Z | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 2838000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 15332000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4315000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 13968000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Asia Pacific · Biotherapeutics Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20220228 | Open filing evidence |
Asia Pacific · Core Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 65050000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 61086000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 25447000 | USD | 20230227 | Open filing evidence |
EMEA · Biotherapeutic Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 1749000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3579000 | USD | 20230803 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 569000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 1631000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1062000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 2368000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 5841000 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1727000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 3471000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1745000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 2748000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 6047000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1728000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 3298000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1570000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13483000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4821000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 10507000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
EMEA · Biotherapeutics Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 7067000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 6872000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 7709000 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20220228 | Open filing evidence |
EMEA · Core Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 6600000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 7859000 | USD | 20230803 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 4121000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 7186000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 3065000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 2317000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11294000 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 4442000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 8979000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4537000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 2141000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 8128000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1586000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 5987000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 4401000 | USD | 20200508 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10723000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 15964000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 3011000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 5241000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 2230000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 8878000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 1453000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 4568000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Biotherapeutic Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 567000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6079000 | USD | 20231103 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 2015000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 5511000 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3324000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7441000 | USD | 20231103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1876000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4117000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 4185000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11856000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3868000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7670000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3803000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7461000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 11258000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1482000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 8708000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 5496000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20190301 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 4821000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 10507000 | USD | 2019-11-07 · 02:14:43.000Z | Open filing evidence |
Biotherapeutic Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 3324000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7441000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1876000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4117000 | USD | 20220805 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 4185000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11856000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3868000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7670000 | USD | 20220805 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7461000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 11258000 | USD | 20200810 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1730000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 7225000 | USD | 20200810 | Open filing evidence |
Biotherapeutic Segment · Operating Segments · Product Sales
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211105 | Open filing evidence |
Biotherapeutic Segment · Product Sales
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
Biotherapeutic Segment · Researchand Development Revenue
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 3324000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7441000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 4185000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11856000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3803000 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16638000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3796000 | USD | 20210507 | Open filing evidence |
Biotherapeutic Segment · Researchand Development Revenue · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 4185000 | USD | 20211105 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 5380000 | USD | 20211105 | Open filing evidence |
Biotherapeutic Segment · Product
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221104 | Open filing evidence |
Biotherapeutic Segment · APAC
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:StatementGeographicalAxis=cdxs:APACMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220509 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 0 | USD | 20211105 | Open filing evidence |
Biotherapeutic Segment · Americas
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 1933000 | USD | 20231103 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 266000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1932000 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 1168000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 3653000 | USD | 20231103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1307000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 2486000 | USD | 20230803 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 2141000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 4199000 | USD | 20220805 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 5733000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 7960000 | USD | 20200810 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 0 | USD | 20200810 | Open filing evidence |
Biotherapeutic Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 567000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 4146000 | USD | 20231103 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 2156000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 3788000 | USD | 20231103 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 2368000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 5841000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1745000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1570000 | USD | 20210507 | Open filing evidence |
Biotherapeutics Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 11978000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 14239000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20230227 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20220228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Operating Segments · Researchand Development Revenue
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Product Sales
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Product Sales · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Researchand Development Revenue
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 20950000 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · APAC
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:StatementGeographicalAxis=cdxs:APACMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · Americas
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 13241000 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 38000 | USD | 20210301 | Open filing evidence |
Biotherapeutics Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:BiotherapeuticsSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-01-01 – 2020-12-31 | 7709000 | USD | 20210301 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20210301 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13483000 | USD | 20210301 | Open filing evidence |
Core Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 8710000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 37503000 | USD | 20231103 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 19308000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 28794000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 126612000 | USD | 20230227 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 31146000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 100774000 | USD | 20231103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 36530000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 69629000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 33099000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 90515000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 32584000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 68397000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 21585000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 35815000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 14229000 | USD | 20220509 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 48106000 | USD | 20230227 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 13005000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 31385000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7506000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 18379000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 10874000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 58156000 | USD | 20220228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 20424000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 41100000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 10589000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 20676000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 10087000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 47073000 | USD | 20210301 | Open filing evidence |
Core Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 126612000 | USD | 20230227 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 31146000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 100774000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 36530000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 69629000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 90515000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 32584000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 68397000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 21585000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 35815000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 14229000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 48106000 | USD | 20230227 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 13005000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 31385000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7506000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 18379000 | USD | 20210806 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 10874000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 58156000 | USD | 20220228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 20424000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 41100000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 10589000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 20676000 | USD | 20200810 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 47073000 | USD | 20210301 | Open filing evidence |
Core Segment · Operating Segments · Product Sales
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 70657000 | USD | 20220228 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 30220000 | USD | 20220228 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 29465000 | USD | 20220228 | Open filing evidence |
Core Segment · Operating Segments · Researchand Development Revenue
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 19858000 | USD | 20220228 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4003000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 17886000 | USD | 20220228 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5774000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 28691000 | USD | 20220228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 21483000 | USD | 20210301 | Open filing evidence |
Core Segment · Product Sales
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 116676000 | USD | 20230227 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 34645000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 65335000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 70657000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 28731000 | USD | 20211105 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 53674000 | USD | 20211105 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 14717000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 24943000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 10226000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 30220000 | USD | 20230227 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 8401000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 18005000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4504000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 9604000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5100000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 29465000 | USD | 20220228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10351000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 24588000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 6249000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 14236000 | USD | 20200810 | Open filing evidence |
Core Segment · Product Sales · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 70657000 | USD | 20230227 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 10226000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 30220000 | USD | 20230227 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 8401000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 18005000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4504000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 9604000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5100000 | USD | 20210507 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 10351000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 24588000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 6249000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 14236000 | USD | 20200810 | Open filing evidence |
Core Segment · Researchand Development Revenue
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 9936000 | USD | 20230227 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3104000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 7398000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 19858000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3853000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 14723000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4003000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 17886000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5774000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 28691000 | USD | 20220228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 21483000 | USD | 20210301 | Open filing evidence |
Core Segment · Researchand Development Revenue · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 19858000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 17886000 | USD | 20230227 | Open filing evidence |
Core Segment · Product
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 28042000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 93376000 | USD | 20221104 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 28731000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 53674000 | USD | 20221104 | Open filing evidence |
Core Segment · APAC
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:StatementGeographicalAxis=cdxs:APACMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 9037000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 16346000 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 23661000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 81243000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 30102000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 57582000 | USD | 20230803 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 24268000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 44530000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 13440000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 20262000 | USD | 20220805 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 25447000 | USD | 20210301 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 7655000 | USD | 20211105 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 15876000 | USD | 20211105 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4747000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 8221000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 18286000 | USD | 20210301 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 3502000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 8522000 | USD | 20200810 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 22863000 | USD | 20210301 | Open filing evidence |
Core Segment · Americas
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 3671000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4589000 | USD | 20230803 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3654000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 8514000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 2307000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4861000 | USD | 20230803 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 16114000 | USD | 20220228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5999000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 12573000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3703000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 6574000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 2871000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 11111000 | USD | 20220228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 3209000 | USD | 20201106 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 7381000 | USD | 20201106 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1173000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 4171000 | USD | 20200810 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 2999000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 13039000 | USD | 20220228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 2706000 | USD | 20201106 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 9620000 | USD | 20201106 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4076000 | USD | 20200810 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 6913000 | USD | 20200810 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 15332000 | USD | 20210301 | Open filing evidence |
Core Segment · Asia Pacific
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 61086000 | USD | 20220228 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 25447000 | USD | 20220228 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 18286000 | USD | 20220228 | Open filing evidence |
Core Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:CoreSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 2624000 | USD | 20231103 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 10484000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 49473000 | USD | 20230227 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 3831000 | USD | 20231103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 11017000 | USD | 20231103 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 13315000 | USD | 20230227 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 2317000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11294000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4537000 | USD | 20210507 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 11548000 | USD | 20230227 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 4401000 | USD | 20210507 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 26831000 | USD | 20220228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 8878000 | USD | 20210301 | Open filing evidence |
Novel Biotherapeutics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 3496000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 2015000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 5511000 | USD | 20230803 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 3496000 | USD | 20230504 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1876000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4117000 | USD | 20230803 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2241000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · Product Sales
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20230504 | Open filing evidence |
Novel Biotherapeutics · Product Sales · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · Researchand Development Revenue · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13521000 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · APAC
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:StatementGeographicalAxis=cdxs:APACMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · Americas
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1666000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1179000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 38000 | USD | 20200228 | Open filing evidence |
Novel Biotherapeutics · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:NovelBiotherapeuticsMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1830000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1062000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 10302000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 13483000 | USD | 20200228 | Open filing evidence |
Performance Enzymes
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 9486000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 33099000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 58156000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 47073000 | USD | 20200228 | Open filing evidence |
Performance Enzymes · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 9486000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 33099000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 58156000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 47073000 | USD | 20200228 | Open filing evidence |
Performance Enzymes · Product Sales
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 8364000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 30690000 | USD | 20230504 | Open filing evidence |
Performance Enzymes · Product Sales · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ProductOrServiceAxis=cdxs:ProductSalesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 8364000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 30690000 | USD | 20230504 | Open filing evidence |
Performance Enzymes · Researchand Development Revenue
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1122000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2409000 | USD | 20230504 | Open filing evidence |
Performance Enzymes · Researchand Development Revenue · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:ProductOrServiceAxis=cdxs:ResearchandDevelopmentRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1122000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2409000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 28691000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 21483000 | USD | 20200228 | Open filing evidence |
Performance Enzymes · APAC
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:StatementGeographicalAxis=cdxs:APACMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 7309000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 27481000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 18286000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 22863000 | USD | 20200228 | Open filing evidence |
Performance Enzymes · Americas
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 918000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2553000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 13039000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 15332000 | USD | 20200228 | Open filing evidence |
Performance Enzymes · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxs:PerformanceEnzymesMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1259000 | USD | 20230504 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 3065000 | USD | 20230504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 26831000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 8878000 | USD | 20200228 | Open filing evidence |